Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Jonas S, Jutzi"'
Publikováno v:
Frontiers in Molecular Biosciences, Vol 11 (2024)
Externí odkaz:
https://doaj.org/article/14c8901f764747f4a4997f90636fb002
Autor:
Jonas S. Jutzi, Anna E. Marneth, María José Jiménez-Santos, Jessica Hem, Angel Guerra-Moreno, Benjamin Rolles, Shruti Bhatt, Samuel A. Myers, Steven A. Carr, Yuning Hong, Olga Pozdnyakova, Peter van Galen, Fátima Al-Shahrour, Anna S. Nam, Ann Mullally
Publikováno v:
Leukemia. 37:359-369
Cancer is driven by somatic mutations that provide a fitness advantage. While targeted therapies often focus on the mutated gene or its direct downstream effectors, imbalances brought on by cell-state alterations may also confer unique vulnerabilitie
Autor:
Jonas S. Jutzi, Anna E. Marneth, Michele Ciboddo, Angel Guerra-Moreno, María José Jiménez-Santos, Anastasia Kosmidou, James W. Dressman, Hongyan Liang, Rebecca Hamel, Patricia Lozano, Elisa Rumi, John G. Doench, Jason Gotlib, Anandi Krishnan, Shannon Elf, Fátima Al-Shahrour, Ann Mullally
Publikováno v:
Blood
Calreticulin (CALR) mutations are frequent, disease-initiating events in myeloproliferative neoplasms (MPNs). Although the biological mechanism by which CALR mutations cause MPNs has been elucidated, there currently are no clonally selective therapie
Autor:
Jonas S. Jutzi, Maria Kleppe, Jennifer Dias, Hans Felix Staehle, Kaitlyn Shank, Julie Teruya-Feldstein, Sudheer Madan Mohan Gambheer, Christine Dierks, Hugh Y. Rienhoff, Jr, Ross L. Levine, Heike L. Pahl
Publikováno v:
HemaSphere, Vol 2, Iss 3 (2018)
Abstract. Despite recent advances, the myeloproliferative neoplasms (MPNs) are attended by considerable morbidity and mortality. Janus kinase (Jak) inhibitors such as ruxolitinib manage symptoms but do not substantially change the natural history of
Externí odkaz:
https://doaj.org/article/9a5226cfef28450b8b2347a82de72292
Autor:
Jonas S. Jutzi, Ann Mullally
Publikováno v:
Blood. 140:2767-2768
Autor:
Anna E Marneth, Jonas S. Jutzi, Chulwoo J. Kim, Charles Laurore, Anastasia Tishena, Frederike Kramer, Azucena V. Rocha, Mohammed Wazir, Lachelle D. Weeks, Joan How, Maximilian F. Stahl, Marlise R. Luskin, R. Coleman Lindsley, Olga Pozdnyakova, Timothy A. Graubert, Ann Mullally
Publikováno v:
Blood. 140:1089-1090
Autor:
Christoph Koellerer, Albert Gründer, Mathijs A. Sanders, Manuela Simoni, Laura Riccetti, Heike L. Pahl, Jerzy-Roch Nofer, Peter J. M. Valk, Jonas S. Jutzi, Carsten Müller-Tidow, Fengbiao Zhou, Samuel Vorbach, Francesco Potì
Publikováno v:
Leukemia, 34(3), 721-734. Nature Publishing Group
Acute myeloid leukemia (AML) carries a 10–100 fold lower mutational burden than other neoplastic entities. Mechanistic explanations for why a low number of mutations suffice to induce leukemogenesis are therefore required. Here we demonstrate that
Autor:
Jonas S. Jutzi, Heike L. Pahl
Publikováno v:
Mediators of Inflammation, Vol 2015 (2015)
It has been known for some time that solid tumors, especially gastrointestinal tumors, can arise on the basis of chronic inflammation. However, the role of inflammation in the genesis of hematological malignancies has not been extensively studied. Re
Externí odkaz:
https://doaj.org/article/bfeb900c488f4faf9e63fcde3208af3d
Autor:
Mathijs A. Sanders, Sandra Kaiser, Wei Wang, Sarolta Bojtine Kovacs, Lars Bullinger, Bruno Cassinat, Annelieke Zeilemaker, Christoph Koellerer, Peter J. M. Valk, Jonas S. Jutzi, Titiksha Basu, Adil Al Hinai, Jenny Ostendorp, Brigitte Schlegelberger, Heike L. Pahl, Emmanuel Raffoux, Doris Steinemann, Maximilian Pellmann, Konrad Aumann
Publikováno v:
Blood, 133(16), 1766-1777. American Society of Hematology
In acute myeloid leukemia (AML), acquired genetic aberrations carry prognostic implications and guide therapeutic decisions. Clinical algorithms have been improved by the incorporation of novel aberrations. Here, we report the presence and functional
Autor:
Jonas S. Jutzi, Ann Mullally
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology, Vol 11 (2020)
Philadelphia-negative myeloproliferative neoplasms (MPN) are malignant bone marrow (BM) disorders, typically arising from a single somatically mutated hematopoietic stem cell. The most commonly mutated genes, JAK2, CALR, and MPL lead to constitutivel